Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28888674 | 0.91 | MGLL (0.32) | — | |
| SCHEMBL28888675 | 0.91 | MGLL (0.32) | — | |
| SCHEMBL29628115 | 0.91 | — | — | |
| SCHEMBL29825364 | 0.84 | AKT1 (0.35) | AKT1OPRM1OPRD1OPRK1 | |
| SCHEMBL17345169 | 0.82 | AKT1 (0.33) | AKT1OPRM1OPRD1OPRK1 | |
| SCHEMBL22455884 | 0.81 | AKT1 (0.33) | AKT1OPRM1OPRD1OPRK1 | |
| SCHEMBL30199847 | 0.80 | AKT1 (0.33) | AKT1 | |
| SCHEMBL21557778 | 0.79 | AKT1 (0.32) | AKT1OPRM1OPRD1OPRK1 | |
| SCHEMBL19733469 | 0.78 | TLR2 (0.33) | — | |
| SCHEMBL29635326 | 0.78 | HSD17B10 (0.34) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11555019-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | Cybrexa 3, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| EP-3996749-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | MAP4, MAP2, TUBB3 | AKT1 1982/4885OPRM1 4138/4885OPRD1 4364/4885 |
| US-12234212-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | AKT1 1982/4885OPRM1 4138/4885OPRD1 4364/4885 |
| US-11555019-B2 | Peptide conjugates of microtubule-targeting agents as therapeutics | MAP4, MAP2, TUBB3 | AKT1 1982/4885OPRM1 4138/4885OPRD1 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.